Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Capitol Hill In Brief

This article was originally published in The Gray Sheet

Executive Summary

Import safety bill: A new draft of the drug portion of the proposed FDA Globalization Act crafted by the House Energy and Commerce Committee and posted on the panel's website July 28 indicates that Congress is continuing its work on the measure, but in separate pieces. The only language pertaining to devices in the draft is the requirement that each drug and device establishment have a unique identification number. However, the House panel is still interested in addressing imported medical device safety, and will most likely take up that section of the bill after the congressional recess ends on Sept. 8, a house staffer said. At a hearing on the act in May, Republican members of the committee's Health Subcommittee, including Rep. Joe Barton of Texas, supported an industry position on the bill that the device components of it should be removed and dealt with separately. Barton opposed requirements in the legislation calling for pre-market inspections of all class II 510(k) devices ("1The Gray Sheet" May 19, 2008, p. 4)

You may also be interested in...



Industry Opposes Idea Of New FDA Inspection Authority, Fee At House Hearing

Several device industry representatives told lawmakers on Capitol Hill May 14 that additional FDA user fees and expansion of pre-approval inspection authority to include less risky, Class II devices should not be part of a proposed bill making its way through Congress. They got support from the Republican members of the panel

Democrats Seek To Overturn Supreme Court Device Liability Decision

Democratic leaders in Congress are vowing to craft legislation to effectively overturn the Supreme Court's ruling that PMA approval pre-empts a patient's right to sue device companies for personal injury

Pandemic Response In US Consumer Health Market: OTC Pain Relief And Cough/Cold Purchases

Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.

UsernamePublicRestriction

Register

MT026399

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel